E-therapeutics finance chief stepping down due to family
Drug discovery company E-therapeutics announced on Monday that Karl Keegan was stepping down from his non-board role as chief financial officer, to focus on “extremely difficult” family circumstances in Ireland.
The AIM-traded firm said his resignation would take effect from 31 December.
It said it was actively looking for a new chief financial officer, during which time non-executive director Michael Bretherton would act as interim CFO.
Bretherton had been a director of seven other AIM quoted companies during the last 10 years, including DeepMatter Group, Nanoco Group, Ceres Power and Tissue Regenix Group.
He has a degree in economics from Leeds University, and is a member of the Institute of Chartered Accountants in England and Wales.
Bretherton’s early career included working as an accountant and manager with PriceWaterhouse for seven years in London and the Middle East.
“We are very saddened that Karl will be leaving e-therapeutics under these circumstances at the end of the year,” said chief executive officer Ali Mortazavi.
“We are grateful to Karl for his contribution to e-therapeutics and wish him the very best in the future.”
At 1348 GMT, shares in E-therapeutics were up 2.09% at 46.5p.